PMID- 17379253
OWN - NLM
STAT- MEDLINE
DCOM- 20070612
LR  - 20161122
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 80
IP  - 19
DP  - 2007 Apr 17
TI  - Antagonism of phosphoramidon-induced antinociception in mice by mu- but not 
      kappa-opioid receptor blockers.
PG  - 1816-20
AB  - Intracerebroventricular (i.c.v.) administration of the neutral endopeptidase 
      24.11-inhibitor phosphoramidon evoked a dose-dependent antinociceptive effect in 
      the mouse acetic acid abdominal constriction test. The present study was 
      conducted to identify the opioid receptor subtype(s) that mediate phosphoramidon 
      antinociception in this paradigm. Mice were pretreated with different opioid 
      antagonists prior to being challenged with phosphoramidon, i.c.v., the mu-opioid 
      agonist sufentanil, s.c., or the kappa-opioid agonist U-50,488H, s.c. Naltrexone 
      significantly attenuated phosphoramidon-induced antinociception at an i.c.v. dose 
      that also blocked both sufentanil and U-50,488H. The mu-opioid antagonist 
      beta-funaltrexamine (beta-FNA) blocked phosphoramidon and sufentanil at an i.c.v. 
      dose that did not block U-50,488H. The kappa-opioid antagonist 
      nor-binaltorphimine (nor-BNI) produced dose-related effects. A low dose (10 
      microg) of nor-BNI had no effect on either phosphoramidon or sufentanil but did 
      reduce U-50,488H antinociception. A higher dose (30 microg) of nor-BNI blocked 
      phosphoramidon, sufentanil, and U-50,488H, suggesting a loss of kappa-opioid 
      receptor selectivity at this dose. These findings suggest that mu- but not 
      kappa-opioid receptors mediate phosphoramidon-induced antinociception in the 
      abdominal constriction test.
FAU - Pruhs, Ronald J
AU  - Pruhs RJ
AD  - Department of Pediatric Dentistry, Marquette University School of Dentistry, 
      Milwaukee, WI 53201-1881, United States.
FAU - Pena, Roehl T
AU  - Pena RT
FAU - Quock, Raymond M
AU  - Quock RM
LA  - eng
GR  - R01 DE006894-06/DE/NIDCR NIH HHS/United States
GR  - DE-10047/DE/NIDCR NIH HHS/United States
GR  - DE-06894/DE/NIDCR NIH HHS/United States
GR  - R01 DA010343-03/DA/NIDA NIH HHS/United States
GR  - R01 DA010047-04/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070222
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Glycopeptides)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Receptors, Opioid, kappa)
RN  - 0 (Receptors, Opioid, mu)
RN  - 5S6W795CQM (Naltrexone)
RN  - 67198-13-4 
      (3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, 
      (trans)-Isomer)
RN  - 72782-05-9 (beta-funaltrexamine)
RN  - T3G94E2LB1 (phosphoramidon)
SB  - IM
MH  - 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, 
      (trans)-Isomer/pharmacology
MH  - *Analgesia
MH  - Animals
MH  - Glycopeptides/antagonists & inhibitors/*pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Naltrexone/analogs & derivatives/pharmacology
MH  - Narcotic Antagonists/pharmacology
MH  - Receptors, Opioid, kappa/agonists/antagonists & inhibitors/physiology
MH  - Receptors, Opioid, mu/agonists/antagonists & inhibitors/*physiology
EDAT- 2007/03/24 09:00
MHDA- 2007/06/15 09:00
CRDT- 2007/03/24 09:00
PHST- 2006/09/06 00:00 [received]
PHST- 2007/01/27 00:00 [revised]
PHST- 2007/02/15 00:00 [accepted]
PHST- 2007/03/24 09:00 [pubmed]
PHST- 2007/06/15 09:00 [medline]
PHST- 2007/03/24 09:00 [entrez]
AID - S0024-3205(07)00178-6 [pii]
AID - 10.1016/j.lfs.2007.02.019 [doi]
PST - ppublish
SO  - Life Sci. 2007 Apr 17;80(19):1816-20. doi: 10.1016/j.lfs.2007.02.019. Epub 2007 
      Feb 22.